CDK4 and neoplasm: In an attempt to leverage this, preclinical investigators have combined several CDK4/6 inhibitors with a variety of immunotherapeutics, demonstrating superior control of tumor growth [37, 57, 78, 79, 85, 86], and the generation of T cell memory which engenders resistance to tumor re-challenge [37].